drugset / Trial / NCT04773977

Clinical Study of IBI362 in Healthy Chinese Male Subjects

NCT04773977

Phase 1 Completed 24 enrolled Innovent Biologics (Suzhou) Co. Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.

Timeline

Start
2021-03-03
Primary completion
2021-03-09
Completion
2021-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Mazdutide Protein / enzyme biologic Subcutaneous

Indications